CN101360495B - 对癌症病人给药mTOR抑制剂 - Google Patents

对癌症病人给药mTOR抑制剂 Download PDF

Info

Publication number
CN101360495B
CN101360495B CN2006800510347A CN200680051034A CN101360495B CN 101360495 B CN101360495 B CN 101360495B CN 2006800510347 A CN2006800510347 A CN 2006800510347A CN 200680051034 A CN200680051034 A CN 200680051034A CN 101360495 B CN101360495 B CN 101360495B
Authority
CN
China
Prior art keywords
cancer
patients
mtor
day
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800510347A
Other languages
English (en)
Chinese (zh)
Other versions
CN101360495A (zh
Inventor
卡米尔·L·贝德罗塞安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Gene Therapeutics Inc
Original Assignee
Ariad Pharmaceuticals Inc
Ariad Gene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals Inc, Ariad Gene Therapeutics Inc filed Critical Ariad Pharmaceuticals Inc
Publication of CN101360495A publication Critical patent/CN101360495A/zh
Application granted granted Critical
Publication of CN101360495B publication Critical patent/CN101360495B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2006800510347A 2005-11-14 2006-11-14 对癌症病人给药mTOR抑制剂 Expired - Fee Related CN101360495B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73676305P 2005-11-14 2005-11-14
US60/736,763 2005-11-14
PCT/US2006/044146 WO2007059106A2 (en) 2005-11-14 2006-11-14 Administration of mntor inhibitor to treat patients with cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100014166A Division CN102579467A (zh) 2005-11-14 2006-11-14 雷帕霉素衍生物在治疗癌症中的用途

Publications (2)

Publication Number Publication Date
CN101360495A CN101360495A (zh) 2009-02-04
CN101360495B true CN101360495B (zh) 2012-03-14

Family

ID=38049229

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800510347A Expired - Fee Related CN101360495B (zh) 2005-11-14 2006-11-14 对癌症病人给药mTOR抑制剂
CN2012100014166A Pending CN102579467A (zh) 2005-11-14 2006-11-14 雷帕霉素衍生物在治疗癌症中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100014166A Pending CN102579467A (zh) 2005-11-14 2006-11-14 雷帕霉素衍生物在治疗癌症中的用途

Country Status (9)

Country Link
US (1) US20070185150A1 (enExample)
EP (2) EP1962839A4 (enExample)
JP (2) JP5709354B2 (enExample)
CN (2) CN101360495B (enExample)
AU (1) AU2006315512B2 (enExample)
CA (1) CA2629714A1 (enExample)
EA (1) EA015922B1 (enExample)
IL (1) IL191356A0 (enExample)
WO (1) WO2007059106A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
EP2419136A4 (en) 2009-04-16 2013-01-02 Merck Sharp & Dohme COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
WO2011024168A2 (en) * 2009-08-26 2011-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Sustained release delivery systems for the prevention and treatment of head and neck cancers
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
WO2012148846A1 (en) * 2011-04-25 2012-11-01 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
BR112014013332B1 (pt) * 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
CN104349779A (zh) * 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN106166296A (zh) * 2016-07-01 2016-11-30 江南大学 一种辅助雷帕霉素治疗多种肿瘤的药物组合物
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
CN115135322A (zh) * 2020-02-21 2022-09-30 韩国高等科学技术学院 包含哺乳动物雷帕霉素靶蛋白信号传导抑制剂作为有效成分的用于预防或治疗癌症的药物组合物
CN114767867A (zh) * 2021-12-22 2022-07-22 中山大学孙逸仙纪念医院 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1545419A (zh) * 2001-04-06 2004-11-10 诸如雷帕霉素和吉西他滨或氟尿嘧淀的抗肿瘤联合
US20050119288A1 (en) * 2003-08-18 2005-06-02 Pfizer Inc Dosing schedule for a novel anticancer agent

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
EP1181938B1 (en) 1993-04-23 2007-11-14 Wyeth Rapamycin conjugates and antibodies
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DK1033128T4 (da) 1993-09-28 2012-03-19 Scherer Gmbh R P Blød gelatinekapselfremstilling
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0000482D0 (en) 2000-01-11 2000-03-01 Norton Healthcare Ltd Enteric coated pharmaceutical formulation
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
EP1399468B1 (en) 2001-05-30 2006-02-15 Novartis AG 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives
EP1478648B1 (en) * 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
UA81265C2 (en) 2002-09-17 2007-12-25 Wyeth Corp Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
DE602004011398T2 (de) 2004-01-08 2009-01-15 Wyeth Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
US7405497B2 (en) 2004-04-13 2008-07-29 Electrovaya Inc. Integrated power supply system
EP1809276A4 (en) * 2004-09-30 2009-06-17 Ariad Pharma Inc PROCESSING PROCESS
JP2008530145A (ja) * 2005-02-15 2008-08-07 ワイス 経口投与可能なｃｃｉ−７７９製剤
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
DE102005017313A1 (de) 2005-04-14 2006-10-19 Volkswagen Ag Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug
US20070105887A1 (en) * 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1545419A (zh) * 2001-04-06 2004-11-10 诸如雷帕霉素和吉西他滨或氟尿嘧淀的抗肿瘤联合
US20050119288A1 (en) * 2003-08-18 2005-06-02 Pfizer Inc Dosing schedule for a novel anticancer agent

Also Published As

Publication number Publication date
EP1962839A2 (en) 2008-09-03
WO2007059106A2 (en) 2007-05-24
JP2009515901A (ja) 2009-04-16
CN101360495A (zh) 2009-02-04
JP2014012721A (ja) 2014-01-23
AU2006315512B2 (en) 2012-11-01
JP5709354B2 (ja) 2015-04-30
IL191356A0 (en) 2009-08-03
US20070185150A1 (en) 2007-08-09
CA2629714A1 (en) 2007-05-24
CN102579467A (zh) 2012-07-18
EA200801309A1 (ru) 2008-10-30
EP1962839A4 (en) 2010-08-25
WO2007059106A3 (en) 2008-06-05
EP2662082A1 (en) 2013-11-13
EA015922B1 (ru) 2011-12-30
AU2006315512A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
JP5709354B2 (ja) ｍＴＯＲ阻害剤投与によるがん患者の治療
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
RU2764116C2 (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN118785911A (zh) 用于治疗肿瘤的药物组合物
US20100266590A1 (en) Combination therapy
JP5758003B2 (ja) 抗癌剤併用療法
CN108025076A (zh) 使用阿吡莫德治疗癌症的方法
TW201639578A (zh) 阿吡莫德之活性代謝物及其用途
CN102065865B (zh) 多发性骨髓瘤治疗
KR20130073948A (ko) 암 치료를 위한 새로운 병용 요법
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
EP3302483B1 (en) Pharmaceutical compositions and use thereof
US20080207644A1 (en) Therapeutic materials and methods
CN119894514A (zh) 药物组合物及其用途
TWI434700B (zh) 放射線治療增強劑
US20240122937A1 (en) Treating cancer in patient with pten inactivating mutation
HK1173387A (en) Use of a rapamycin derivative for the treatment of cancer
TW202535398A (zh) 用於治療癌症之包含光學活性氮雜雙環衍生物之醫藥
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
HK1118704B (en) Radiotherapy enhancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ELIYADE PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: ELIYADE GENE THERAPY COMPANY

Effective date: 20090904

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090904

Address after: Massachusetts, USA

Applicant after: Ariad Gene Therapeutics Inc.

Address before: Massachusetts, USA

Applicant before: Ariad Gene Therapeutics Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120314

Termination date: 20151114

EXPY Termination of patent right or utility model